RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.
“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”
Breaking News
FDA Accepts RedHill Biopharma’s NDA for Talicia
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
07.16.19
Related Breaking News
-
Analytical Services | Breaking News | Industry News | Promotions & Moves
Idifarma Strengthens Spray Drying Capabilities
Partners with industry expert Stefano Console, who will serve as scientific advisor.Contract Pharma Staff 12.01.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Facilities | Industry News
CDMO Stelis Continues Expansion
Starts next phase of investment into its biologics manufacturing facility.Contract Pharma Staff 12.01.20
-
Aseptic Processing | Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News | Scale-up/Technology Transfer
Recipharm Inks Covid-19 Vax Pact with Moderna
Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).Contract Pharma Staff 12.01.20
-
Breaking News | Drug Development | Formulation Development | Industry News
Vectura, Kinaset Partner to Develop Asthma Treatment
Licenses VR588 to Kinaset, Vectura will provide formulation development services to support Phase I studies and ultimately commercialization.Contract Pharma Staff 11.30.20
-
Breaking News | Clinical Trials | Industry News
SGS Initiates U.S. COVID-19 Clinical Trials
Phase 2/3 trial will examine the safety, tolerability, and efficacy of Sarconeos (BIO101) to treat COVID-19 related respiratory failure.Contract Pharma Staff 11.30.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Formulation Development | Industry News
Lonza Expands Development, Mfg. Capabilities at Bend Site
Investment will add 11 new suites for particle engineering and drug product capacity to improve program lead times.Contract Pharma Staff 11.30.20
-
APIs | Breaking News | Facilities | Industry News
CordenPharma Colorado Increases US Peptide Manufacturing Capacity
Long-term expansion initiative approved to further increase flexibility, efficiency and ultimately, cost-effective production.Contract Pharma Staff 11.25.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
CureVac and Wacker Sign Contract for Manufacturing of Covid-19 Vaccine Candidate
Manufacturing at Wacker’s biotech site in Amsterdam is scheduled to start in the first half of 2021.Contract Pharma Staff 11.24.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Supply Chain
Lonza and Be The Match BioTherapies Enter CGT Partnership
Will expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network.Contract Pharma Staff 11.24.20
-
Bio News | Breaking News | Facilities | Industry News
Samsung Biologics Breaks Ground on 'Super Plant'
When completed, the CDMO says it will be the world's largest bio-manufacturing facility.Contract Pharma Staff 11.24.20
-
Breaking News | Facilities | Industry News | Injectables | Parenterals
ApiJect Systems Approved for $590 Million Loan
Supports building a U.S.-based facility with surge capacity to produce up to 3 billion single-dose prefilled plastic injectors per year.Contract Pharma Staff 11.24.20
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
Syngene and 3DC Sign 5-year Collaboration
Partner on discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.Contract Pharma Staff 11.24.20
-
Breaking News | Facilities | Industry News
Abenza Upgrades Chemistry GMP Suites
Appoints new leadership at Bristol PA site.Contract Pharma Staff 11.24.20
-
Breaking News | Clinical Trials | Industry News
Merck Acquires OncoImmune for $425M
Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19.Contract Pharma Staff 11.24.20
-
Aseptic Processing | Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Fill/Finish | Industry News | Injectables | Lyophilization | Parenterals
Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations
Construction currently underway; expected to be completed in 2021.Contract Pharma Staff 11.24.20
